TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05765474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Variable
Description: This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Practice Variable
Description: This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
Study: NCT05815888

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound Score
Description: one hemithorax is consisted of 6 scanning zones. Each of them are evaluated via ultrasonography in terms of presence of vertical B lines (\<4 B lines: 1 point; \>3 B lines or thick B lines: 2 points; marked disturbance in pleural line: 3 points). Higher scores reflect worse outcomes such as atelectasis and consolidation, and totally 12 zones are evaluated.~Three different time points are defined for LUS:~T1: 5 minutes after orotracheal intubation T2: At the end of surgery, before extubation T3: 30 minutes after extubation, in postanesthesia care unit.~DeltaT= T2LUS-T1LUS~Blood gas analysis will be evaluated hourly throughout the surgery
Study: NCT03314428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait retraining
Description: Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
Study: NCT06477770

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Clorhexidine soap
Description: surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clorhexidine soap
Description: surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 75 g of sucrose will be administered to the surgical wound at 8:00 am every day, once a day, and then it will be covered with sterile gauze.
Study: NCT06565312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flora Power Probiotic Vaginal Suppository
Description: The suppository contains Microcrystalline Cellulose, Ascorbic Acid, Vitamin C, Gelatin Capsule, Vaginal Probiotic Blend (Lactobacillus fermentum LF61, Lactobacillus acidophilus LA85, Lactobacillus plantarum Lp90), Magnesium Stearate, and Silicon Dioxide.
Study: NCT05809947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: One bout of neuromuscular electrical stimulation in conjunction with forced lengthening contractions on one leg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: One bout of neuromuscular electrical stimulation in conjunction with forced lengthening contractions on one leg
Study: NCT05763407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIRE1 System
Description: FIRE1 System
Study: NCT05674617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: WET will be conducted in accordance with the Written Exposure Therapy for PTSD: A Brief Treatment Approach for Mental Health Professionals Manual and the VA evidence-based practice (EBP) rollout training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Education
Description: The 5-session PTSD psychoeducation and skills protocol we will be utilizing for our PTSD education control condition was developed by PTSD clinical team (PCT) clinicians at the Washington DC VA Medical Center as a group protocol for Veterans admitted to the PCT and who were on the waitlist for individual therapy with an EBP for PTSD. The PTSD 101 protocol consists of psychoeducation on topics related to PTSD symptoms and an introduction to PTSD-related coping skills. Its duration and structure will be similar to WET (5 weekly individual 50-minute sessions). To parallel the time an attention given in individual WET sessions more closely, participants will quietly review any written materials or videos that are a part of the manualized curriculum for 30 minutes of the session, bookended by a 10-minute check-in with their provider on symptoms and introduction to new materials at the start of session and another 10-minute debrief of reviewed materials at the end of session.
Study: NCT06571942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol / Umeclidinium (25/62.5 mcg)
Description: One inhalation daily from Ellipta device for three months
Study: NCT05518201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo among 18-45 yrs
Description: Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo among 9-17 yrs
Description: Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
Study: NCT05366699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary lymphadenetomy alone
Description: oncologic axillary lymphadenectomy
Study: NCT04398849

Intervention type: BIOLOGICAL
Intervention: Licenced 4CMenB Vaccine
Description: Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
Study: NCT06571942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)
Description: One inhalation daily from Ellipta device for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)
Description: One inhalation daily from Ellipta device for three months
Study: NCT05738226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiCare@Home, wearable multimodal seizure monitoring system
Description: Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch).
Study: NCT05574530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colon-delivered multivitamin supplement
Description: 6-week intervention of one dietary supplement a day, containing vitamin B2 (10mg), vitamin B3 (4mg), vitamin B6 (1.4mg), vitamin B9 (400μg), vitamin C (200mg) and vitamin D3 (15ug).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: 6-week intervention of one dietary supplement a day, containing 200 mg of microcrystalline cellulose.
Study: NCT06553560

Intervention type: OTHER
Group type: OTHER
Intervention: Parasternal Block and Recto-İntercostal Fascial Plane Block
Description: Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2 cm lateral to the sternal border to visualize the T2-T4 intercostal space and to identify the pectoralis major muscle, intercostal muscle, and pleura. 10 ml of 0.25% bupivacaine local anesthetic is administered between the pectoralis major and intercostal muscle using an in-plane approach with a 100 mm needle. In addition, a Recto-Intercostal Fascial Plane Block is performed with a high-frequency linear USG probe. The probe is placed 2-3 cm lateral to the xiphoid so that the rectus abdominis muscle and 6-7th cartilages are visualized. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique and 1-2 ml of saline is injected. After observing the spread to the target plane, 20 ml of 0.25% bupivacaine is applied. The same process is repeated bilaterally.
Study: NCT06495424

Intervention type: DRUG
Intervention: Capsaicin 8% Patch Kit,1
Description: Repeat applications every 12 weeks in patients with PDPN of the feet.
Study: NCT06353243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bilateral alternating stimulation
Description: positive touch intervention provided by parent to infant using alternating stimulation
Study: NCT05836935

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multislice CT scan of the paranasal sinuses.
Description: MSCT scan using GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) , Toshiba Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Or Canon Aquilion Prime SP 160 -multidetector- row CT scanner (Canon Medical Systems, Tochigi, Japan) Thin slice Axial scans will be taken at 0.625-1.0 mm slice thickness, commencing from the hard palate till above the end of frontal sinuses, coronal and sagittal multiplanar reconstruction images will be obtained.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI examination of the paranasal sinuses
Description: MRI imaging using Philips Achieva 1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea 1.5T MRI device (Siemens Healthineers, Germany) for suspected intracranial and orbital complications.
Study: NCT06235606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]
Description: Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.5milligram (50micrograms)
Description: Dexmedetomidine is a full α₂ adrenergic receptor agonist roughly eight times more selective for the α₂ receptor than clonidine.
Study: NCT06553456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Serum Albumin
Description: The experimental drug was administered at a dose of 20 g/ day for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Serum Albumin
Description: The positive control drug was administered at a dose of 20 g/ day for 7 days.
Study: NCT05151393

Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring vitamin D3 level
Description: Measuring vitamin D3 in both groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring vitamin D3 level
Description: Measuring vitamin D3 in both groups
Study: NCT05593731

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dental implants with melatonin gel
Description: platelet rich fibrin membrane around dental implants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dental implants with melatonin gel
Description: platelet rich fibrin membrane around dental implants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dental implants with melatonin gel
Description: platelet rich fibrin membrane around dental implants
Study: NCT06172855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at ST36
Description: Electroacupuncture at ST36, which located at the anterior aspect of the lower leg, 3 cun below ST 35, one finger-breadth (middle finger) from the anterior crest of the tibia. Twice or 3 times per week, for 6 weeks.
Study: NCT05820672

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05250778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Room intervention
Study: NCT05497583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetone based HEMA -free universal Adhesive
Description: Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
Study: NCT05390450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Popliteal Plexus Block
Description: Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
Study: NCT05501808

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cerasmart
Description: the patient received a crown made of cerasmart ceramic
Study: NCT05390450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Fascia Iliaca block
Description: Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
Study: NCT06496321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Saphenous vein harvest
Description: The conventional one involves harvesting only the vein, without perivascular tissue or the nerve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No touch Saphenous vein harvest
Description: During the extraction of the saphenous vein using the no touch technique, it is sectioned with the perivascular adipose tissue and the saphenous nerve of the leg.
Study: NCT06106321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transalveolar crest maxillary sinus floor lift
Description: Transalveolar crest maxillary sinus floor lift + bone grafting + implant implant is used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transalveolar crest parietal maxillary sinus floor secondary lift
Description: Transalveolar crest parietal maxillary sinus floor secondary lift + bone grafting + implant implantation were used body
Study: NCT05501808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enamic
Description: the patient received a crown made of enamic ceramic
Study: NCT05589038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Wash/Shampoo
Description: Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Wash/Shampoo
Description: Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Lotion
Description: Parent participant will use the baby lotion on baby participants at least once daily.
Study: NCT05497583

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isopropanol based HEMA- free universal Adhesive
Description: Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
Study: NCT05699291

Intervention type: OTHER
Intervention: Sentinel node detection technique
Description: Patients cared for by a surgeon for histologically proven breast cancer and for whom an indication for detection of the sentinel lymph node is posed.
Study: NCT05340257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin ES
Description: Amoxicillin and clavulanic acid in fixed dose combination will be administered
Study: NCT05055115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Eustachian Tuboplasty
Description: Balloon Eustachian Tuboplasty of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
Study: NCT05436899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LapSim training
Description: Complete 4 courses, each of 12 weeks, of virtual reality simulation on LapSim surgical simulator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LapSim training
Description: Complete 4 courses, each of 12 weeks, of virtual reality simulation on LapSim surgical simulator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LapSim exam
Description: Completed at the beginning and at the end of each of the 4 courses the corresponding exam task.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LapSim exam
Description: Completed at the beginning and at the end of each of the 4 courses the corresponding exam task.
Study: NCT06039397

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semifowler 30' Right Lateral Body Position
Description: Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semifowler 30' Right Lateral Body Position
Description: Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees
Study: NCT06030908

Intervention type: PROCEDURE
Intervention: Reconstruction of Achilles tendon insertion
Description: knotless double-row anchor fixation of the achilles tendon insertion
Study: NCT05857358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lipoaspiration
Description: Adipose tissue harvest will be conducted by a surgeon under under local and intra-veinous sedation anesthesia. Once the patient is asleep and just before the laying of the operating drapes, the skin will be thoroughly disinfected, in order to avoid bacteriological contamination. Each entry point will be disinfected with betadine before and regularly during the procedure and will receive local anesthesia.~The lipoaspiration sites will be infiltrated using a closed system, thanks to a Khoury canula. Adipose tissue will be harvested after waiting at least 5 minutes, in order to limit hematoma and excessive blood harvesting. A 3mm incision will be made then the tissue collection will be performed using a canula, manually, by gentle aspirations into a syringe then directly transferred into a connected sterile bag.~The incision will be closed with 1 stitch of 6-0 absorbable and a paraffin gauze dressing. Then, patient will be awaken and transported to the recovery room.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)
Description: Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~* 2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~* 2 for the sublingual glands (0.5mL for each gland)~* 2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose.
Study: NCT06326034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 5 mg orally given once daily for four months.
Study: NCT06444321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTERCARE-HF
Description: Develpent of an individualized treatment and follow-up plan tailored to co-morbidities, risk areas, cognitive function and functional level as well as the patients' symptoms and needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INTERCARE-HF
Description: Develpent of an individualized treatment and follow-up plan tailored to co-morbidities, risk areas, cognitive function and functional level as well as the patients' symptoms and needs.
Study: NCT05507034

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Each intervention is performed at 4 timepoints namely: before surgery, i.e. baseline (T0), 1-3 weeks post-surgery (T1), 3 months post-surgery (T2) and 1 year post-surgery (T4)
Study: NCT06571942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg
Description: Two inhalations twice daily form pMDI device for three months
Study: NCT06409689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine fumarate low dose
Description: The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.1 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine fumarate high dose
Description: The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.5 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine fumarate moderate dose
Description: The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.35 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
Study: NCT06409689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: The first loading dose of morphine was 4 mg in all patients after operation. The PCA dose of the patients was 1 mg, and the locking interval was 6 min. A supplemental dose of 2 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 60 mg.